MedTrace Logo

Evaluating the SUBLOCADE Treatment Exit Strategy

NCT05878210 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 12

Last updated 2026-01-22

No results posted yet for this study

Summary

The purpose of this study is to observe and assess the successful taper and opioid withdrawal experience after participants stop receiving SUBLOCADE because their healthcare provider determines their disease symptoms have been controlled for at least 9 months and they, together with their healthcare provider, plan to discontinue MOUD.

Conditions

Sponsors & Collaborators

  • Indivior Inc.

    lead INDUSTRY

Principal Investigators

  • (804) 594-4488 · Indivior Inc.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-11-24
Primary Completion
2025-05-09
Completion
2025-05-09

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05878210 on ClinicalTrials.gov